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ABSTRACT
Introduction Metacarpal shaft fractures (MSF) are 
common traumatic hand injuries that usually affect young 
people of working age. They place a significant burden 
on healthcare resources and society; however, there is a 
lack of evidence to guide their treatment. Identifying the 
most beneficial and cost- efficient treatment will ensure 
optimisation of care and provide economic value for the 
National Health Service. The aim of this study is to assess 
the feasibility of a randomised controlled trial comparing 
surgical and non- surgical treatment for MSF in adults.
Methods and analysis This is a multicentre prospective 
cohort study, with a nested qualitative study consisting of 
patient interviews and focus groups, and an embedded 
factorial randomised substudy evaluating the use of text 
messages to maximise data collection and participant 
retention. The outcomes of interest include eligibility, 
recruitment and retention rates, completion of follow- up, 
evaluation of primary outcome measures, calculation 
of the minimal clinically important difference (MCID) for 
selected outcome measures and establishing the feasibility 
of data collection methods and appropriate time- points 
for use in a future trial. Data will be captured using a 
secure online data management system. Data analyses 
will be descriptive and a thematic inductive analysis will 
be used for qualitative data. Minimum clinically important 
effects for each patient- reported outcome measure will be 
estimated using anchor- based responsiveness statistics 
and distribution- based methods.
Ethics and dissemination This study has received 
ethical approval from the Research Ethics Committee and 
the Health Research Authority (REC reference 20/EE/0124). 
Results will be made available to patients, clinicians, 
researchers and the funder via peer- reviewed publications 
and conference presentations. Social media platforms, 
local media and feedback from the Patient Advisory Group 
will be used to maximise circulation of findings to patients 
and the public.
Trial registration number ISRCTN13922779.
INTRODUCTION
Metacarpal shaft fractures (MSF) are common 
traumatic hand injuries reported to represent 
18%–31% of hand fractures.1–4 They usually 
affect young adult males, often in the third 
decade of life,1 5 with the fourth and fifth 
metacarpal most commonly injured.1–6
In 2016, there were 23.5 million accident 
and emergency (A&E) department atten-
dances in the UK with fractures being the 
second most common reason for presen-
tation.7 As hand fractures make up 25% of 
all A&E attendances8 and MSF comprise 
18%–31% of hand fractures,1–4 MSF there-
fore place a significant burden on healthcare 
resources.
MSF predominantly affect those of working 
age2–4 8 9 and are thus associated with signifi-
cant cumulative morbidity.10 Missed time off 
work significantly increases the economic 
burden of MSF.10 However, there is no 
UK- specific data on the healthcare- associated 
costs, socioeconomic, or societal costs of 
these injuries.
There is wide variability in the management 
of MSF. MSF can be managed non- surgically 
with appropriate reduction and immobil-
isation,11 12 or surgically using a variety of 
Strengths and limitations of this study
 ► Provides comprehensive information to inform the 
design and implementation of a future trial compar-
ing treatments for metacarpal shaft fractures (MSF), 
including evaluation of multiple outcome measures 
and calculation of minimal clinically important dif-
ference to inform future sample size calculations.
 ► Provides complementary person- centred insight 
into MSF and research design, conduct and delivery 
through embedded qualitative assessments.
 ► Evaluates effective text message strategies for 
maximising data collection and retention in research 
studies.
 ► A detailed cost evaluation is a particular strength of 
the study and will deliver a comprehensive analysis 
of the costs of treatments available for MSF.
 ► Limited assessment of randomisation.
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different techniques, including Kirschner- wires (K- wires), 
intraosseous wires, interfragmentary compression screws, 
plates or external fixators.13
A systematic review undertaken in 2019 of treatment 
interventions for MSF identified 699 records and no 
randomised controlled trials (RCTs) comparing surgical 
to non- surgical treatments.14 The only retrospective 
cohort study had several key limitations including small 
patient numbers, low follow- up rate (17%) and lack of 
use of a patient- reported outcome measure (PROM) vali-
dated in MSF.15 A search of the WHO ISCTRP portal also 
revealed no ongoing or registered trials worldwide.14
Rationale for study
There is a lack of good quality, large comparative trials to 
guide the treatment of MSF. There are no published or 
ongoing RCTs or cohort studies comparing surgical versus 
non- surgical treatment for MSF. In addition, though the 
use of PROMs in both the clinical and research setting 
has increased in recent years, there is no evidence of reli-
ability, validity and responsiveness of PROMs in MSF.
There are several gaps in the literature:
 ► No consensus on acceptable parameters of deformity 
or displacement, leading to widespread variation in 
treatment
 ► No core outcome sets for hand trauma, so we do not 
know which outcome measures are best suited for the 
study of MSF
 ► No qualitative data exploring patient experience of 
MSF and their treatment
 ► No evaluation of the cost- effectiveness of treatment 
modalities for MSF
 ► No high- quality published evidence comparing treat-
ment modalities for MSF
The lack of existing evidence supports the need for a 
well- designed, pragmatic, multicentre RCT to identify the 
most beneficial and cost- efficient treatment for MSF in 
adults. This study aims to assess the feasibility, accepta-
bility and practicality of such a trial by providing infor-
mation about study design, number of eligible patients, 
recruitment, completion of follow- up, selection of appro-
priate outcome measures, assessment of minimal clini-
cally important difference (MCID) for selected outcome 
measures, costs of treatments and measures to optimise 
recruitment, engagement and retention in a future trial.
Study objectives and purpose
The overall purpose of this study is:
1. To investigate the feasibility and acceptability of con-
ducting a multicentre RCT to assess the clinical and 
cost- effectiveness of surgical and non- surgical treat-
ment for MSF in adults.
2. To provide complementary, detailed and person- 
centred insight that will inform RCT design through 
the identification of barriers to participation among 
patients with MSF, and to develop novel solutions to 
engage these cohorts in research.
The objectives of the study (table 1) were developed 
at a MSF Consensus Workshop, held by the Centre for 
Evidence Based Hand Surgery in Nottingham, November 




FACTS is an observational, multicentre, prospective cohort 
study. Treatments will not be randomly allocated; patient 
care will be determined in the usual way as per the treating 
clinician.
Patients who meet the eligibility criteria (table 2) will 
be recruited from hand fracture clinics at participating 
National Health Service (NHS) hospitals. Where partic-
ipants have multiple MSF with potentially variable frac-
ture patterns, a single digit will be selected as the ‘study 
finger’. Participants with additional hand or upper 
limb injuries will be included and the latter recorded. 
Written informed consent will be obtained from all 
participants by an appropriately trained research asso-
ciate prior to entering the study. Thereafter, participants 
will be reviewed in a face- to- face clinic visit at 6 weeks 
and remotely at 3 and 6 months. This was supported by 
previous studies of MSF reporting full range of motion in 
almost all patients by 6 months.17 Furthermore, previous 
studies in similar patient cohorts with follow- up of 12 
months or longer suffered high drop- rates or struggled to 
recruit adequate numbers of participants. A participant 
pathway flowchart is illustrated in figure 1.
A nested qualitative study consisting of two elements, 
patient interviews and focus groups, will be conducted 
to provide patient- centred insight into study procedures 
and explore the individual impact of the injury. Partici-
pants will be selected from the prospective cohort study, 
using purposive sampling that prioritises young males, 
and further written informed consent separately sought 
for this element of the study.
A detailed cost evaluation to establish the costs of treat-
ments for MSF through representative micro- costing will 
be undertaken. Resource use directly linked to the MSF 
and its sequela and/or complications over the 6 months 
of follow- up will be recorded for each participant. Unit 
cost data will be obtained from national databases such 
as NHS reference costs, the British National Formu-
lary (BNF) and Personal Social Services Research Unit 
(PSSRU) Costs of Health and Social Care.18
A two by two by two factorial randomised substudy will 
be nested within the main cohort study. Once participants 
have consented to the cohort study or qualitative study, they 
will be randomised to the following interventions to eval-
uate the use of text messages in maximising data collection 
and participant retention; frequency of text messages—ei-
ther fortnightly or monthly; two- way communication—text 
message requiring a response from the participant versus a 
notification message only; and personalisation—a person-
alised message versus a standard automated message.
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Treatment groups
Participants will enter a group according to their primary 
mode of treatment on enrolment into the study. Patients 
will undergo standard care as per their treating clinician. 
This will be decided by their clinical care team and will 
not be affected by their involvement in the study. Treat-
ment groups will be defined as follows;
Surgery: any surgical treatment, defined as insertion of 
metal via an open or percutaneous approach in an oper-
ating theatre, such as open reduction internal fixation, 
closed reduction internal fixation, intramedullary fixa-
tion or wiring, extramedullary wiring or external fixation.
Non- surgical treatment: any ‘non- surgical’ treatment, 
defined as regimens with or without reduction (partial or 
complete) of the fracture, any type of splinting or cast, 
and/or immediate or delayed mobilisation delivered in a 
clinic or therapy room environment.
Outcomes
Participants will be invited to attend a research clinic at 
6 weeks following injury. During this visit, clinical assess-
ments of their hand including range of movement, grip 
strength and presence of rotational deformity or extensor 
lag will be recorded. Radiographs taken as part of routine 
clinical care will also be reviewed. The location, fracture 
morphology, amount of shortening, angulation and pres-
ence of step- off deformity on initial radiographs at presen-
tation will be recorded. Complications will be identified 
by review of the patients’ healthcare records at 6 weeks, 
3 months and 6 months. Cosmesis will be assessed from 
question 10 of the Patient Evaluation Measure (PEM), at 
6 weeks, 3 months and 6 months. Participant- reported 
complications will be recorded at the 6- week research 
clinic visit.
The following PROMs were selected for use following 
discussions between clinicians, patients, therapists and 
researchers at the MSF consensus workshop.16 They 
were prioritised due to their ease of use and validity and 
will be collected at baseline, 6 weeks, 3 months and 6 
months.
Patient Evaluation Measure
The PEM consists of 11 items relating to hand function 
and appearance, each scored from one to seven from 
best/normal to worst. It is the PROM of choice in the 
British Society for Surgery of the Hand (BSSH) National 
UK Hand Registry ( www. ukhr. net) and has been demon-
strated to be reliable, valid and responsive for assessing 
hand disorders.19 20
Table 1 Study objectives
How objective will inform the definitive trial Objective
Recruitment for a future trial 1. Define eligibility criteria for the future trial, which correctly identify appropriate 
patients for whom a treatment decision is suitable
2. Estimate the proportion of referred NHS patients who meet these eligibility 
criteria
3. Assess recruitment and retention rates
Outcomes for use in a future trial 4. Evaluate outcomes for use as primary and secondary outcomes
5. Calculate minimal clinically important difference for the proposed primary 
outcome measure
6. Investigate feasibility of collecting outcome data frequently, in order to capture 
subtle improvements in patient- assessed or clinician- assessed outcomes
Follow- up 7. Estimate follow- up and outcome completion rates for both clinic and remotely 
assessed outcomes
8. Explore optimum time- points for follow- up
Sample size calculation 9. Estimate the sample size required for a definitive study
Use of remote assessments in a future trial 10. Evaluate the utility and acceptability of remote completion of health resource 
use questionnaires to assess the impact of care on health service use and 
productivity
11. Evaluate the utility and acceptability of remote, electronically administered 
patient assessments
Economic assessment 12. Inform the design of a future cost- effectiveness analysis by exploring the 
costs of treatment modalities through capture of NHS resource use and 
representative micro- costing
Patient- centred insight into research design, 
conduct and delivery
13. To explore participant experience of MSF, treatment and recovery
14. To explore participant experience of research processes and study burden 
associated with outcome measures
15. To gain recommendations on future study design and mechanisms to facilitate 
study delivery
Facilitate engagement and retention among 
patients with MSF in a future trial
16. To explore the use of health technology applications and social media in 
optimising participation and engagement in research
MSF, metacarpal shaft fractures; NHS, National Health Service.
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Patient-reported outcomes measurement information system 
upper extremity
The PROMIS UE (PROMIS UE Item Bank V.2.0) is a 
computerised adaptive test, developed by the United 
States National Institute of Health using item response 
theory. It has been validated in upper limb fracture and 
is designed to minimise patient burden and theorised 
to measure latent traits more precisely than existing 
PROMs.21 For participants who do not engage with 
electronic means, a paper- based short- form alternative 
version is available.
Shortened Disabilities of the Arm, Shoulder and Hand Outcome 
Measure (QuickDASH)
The Disabilities of the Arm, Shoulder and Hand Score 
(DASH) is the most commonly used PROM in hand and 
wrist trauma and has consistently demonstrated good reli-
ability, validity and responsiveness in several psychometric 
studies.22 It consists of 11 items, developed from the orig-
inal 30- item DASH to improve practicality and eliminate 
item redundancy.23
European Quality of Life Questionnaire (EQ-5D-5L)
The EQ- 5D- 5L is a validated, generalised and standardised 
instrument comprising a Visual Analogue Scale (VAS) 
measuring self- rated health and a health status instru-
ment, consisting of a five- level response for five domains 
related to daily activities.24 This standardised measure of 
health status provides a simple, generic measure of health 
for clinical and economic appraisal.25
Global Rating of change (GROC)
The GROC scale is commonly used as an anchor when 
calculating MCID. It is designed to quantify a patient’s 
improvement or deterioration over time, thus providing 
a means of measuring self- perceived change in health 
status.26 A 7- point scale ranging from −3 (very much 
worse) to +3 (very much better), with 0 indicating 
‘unchanged’, will be used.
Sample size and Justification
As this is a feasibility study, formal sample size calculations 
for between- group comparisons are not appropriate. 
However, we will seek to include as many as 84 participants 
in the study, aiming for comparable numbers in each 
treatment group. This sample size will enable estimation 
of recruitment fraction with margin of error (half width 
of 95% CI) of <9 percentage points and of proportions 
estimated from the recruited sample, such as complete-
ness of follow- up, to within 13 percentage points.
A purposive sample of 12–16 participants, who indi-
cate a willingness to be interviewed and/or attend focus 
groups, will be recruited to the qualitative study. Partici-
pants who decline to participate in the main cohort study 
will also be invited for interview.
Table 2 Eligibility criteria
Inclusion 
criteria
 ► Adults 16 years or older
 ► Radiologically confirmed metacarpal shaft 
fracture
 ► Acute metacarpal shaft fracture affecting 
the index to little finger(s), presenting within 
10 days of injury
 ► Willing and able to give informed consent
 ► Ability to understand English
Exclusion 
criteria
 ► Fracture(s) of the thumb
 ► Fractures extending into the joint surface
 ► Fracture(s) of the metaphyseal base and/or 
neck of the metacarpal
 ► Fracture(s) associated with dislocation at 
the carpometacarpal joint or other adjacent 
joint dislocation
 ► Open fractures
 ► Undisplaced fractures, defined as those 
with a visible fracture line on radiographs 
but anatomical alignment, that is, the bone 
fragments remain aligned with no evidence 
of movement of the fracture fragments 
on anteroposterior, lateral or oblique 
radiographs
 ► Patients who would not be able to adhere 
to study procedures or complete the study 
questionnaires
Figure 1 Study flow diagram. MSF, metacarpal shaft 
fractures. SMS, Short Message Service.
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Analysis of outcomes
The outcomes of interest include feasibility outcomes 
relating to; assessment of eligibility, recruitment and 
retention rates; completion of follow- up; evaluation 
of outcome measures and calculation of the MCID 
for selected outcome measures using quantitative and 
qualitative assessments; and establishing the feasibility 
of data collection methods and appropriate time- points 
for use in a future trial. To address these feasibility aims, 
data analyses will primarily be descriptive with 95% CIs 
to quantify uncertainty in estimates where appropriate.
MCID evaluation
Minimum clinically important differences for each 
PROM at 3 months will be estimated using three anchor- 
based responsiveness statistics: (1) standardised response 
mean; (2) effect size and (3) Guyatt’s Responsiveness 
Index. An estimation of the MCID will also be calculated 
by distribution- based methods, using the SE of measure-
ment, SD and effect size. The minimal detectable change 
will also be calculated to ensure the MCID is greater than 
the measurement error of the PROM. The sensitivity and 
specificity of the PROM will be assessed in conjunction 
with the MCID, as calculated above.
Costing of interventions
Direct observation of procedures will be used to produce 
a ‘micro- cost’ estimate for surgical and non- surgical 
treatments by combining resource use with unit costs 
provided by hospital finance departments. Duration of 
each procedure, theatre staffing, consumables, imaging, 
supplementary devices, postoperative recovery time and 
rehabilitation inputs will be recorded from primary 
sources, such as theatre log systems and patients’ elec-
tronic and paper clinical records. Standard unit costs will 
be used to estimate NHS costs of care in the 6- month post- 
treatment. Unit cost data will be obtained from national 
databases such as the BNF and PSSRU Costs of Health 
and Social Care 2019.18
There is a need to define the economic morbidity of 
MSF in terms of the costs of treatment and associated 
resource use, productivity losses and additional costs 
incurred by patients during the course of their treatment 
and recovery. Identifying the costs of treatments will help 
to establish the feasibility of collecting utility and cost data 
in a future trial, as well as devising methods for accurately 
collecting such data to ensure robust cost- effectiveness 
comparisons in a future trial.
Qualitative analysis
A thematic, inductive approach as described by 
Braun and Clarke27 will be used to analyse inter-
view and focus group data. We will adopt a six- phase 
systematic approach consisting of (1) data familiarisa-
tion—reading and re- reading the data; (2) generation 
of initial codes—generating succinct labels (codes) 
that identify important features of the data that might 
be relevant to answering the research question; (3) 
identification of themes through merging and grouping 
of codes—to identify significant broader patterns of 
meaning (potential themes) and collating data rele-
vant to each theme; (4) review of generated themes—
checking themes against the dataset and refining them 
where necessary; (5) defining and naming themes—de-
veloping a detailed analysis of each and deciding the 
informative name for each theme and (6) finalisation 
of themes and generation of a final report—weaving 
together the analytic narrative and data extracts, and 
contextualising the analysis in relation to existing liter-
ature. NVivo 12 or above Pro software (QSR Interna-
tional Pty, Victoria, Australia) will be used for analysis.
Patient and public involvement statement
Patients and the public have played a central role in 
selecting the management of MSF as a key research 
priority and developing the proposed study. The Hand 
Surgery Research Prioritisation workshop, attended by 
clinicians, therapists and patients, recommended the 
management of MSF as a key research priority.28 This was 
ratified by the James Lind Alliance Priority Setting Part-
nership on Common Conditions Affecting the Hand and 
Wrist.16 This joint collaboration with the BSSH involved 
261 individuals, of which 41% were patients/carers and 
59% were clinicians.16
Furthermore, a MSF Consensus Workshop was held 
in Nottingham in 2018, bringing together patients with 
MSF, clinicians, therapists and researchers to share their 
experiences and develop the PICO framework for a 
future multicentre trial.16 Group discussions informed 
the eligibility criteria and identified areas of focus for 
the feasibility work. Selection of patient- centred outcome 
measures, timing of assessments and follow- up for the 
proposed study were discussed. A variety of outcome 
measures were reviewed and the QuickDASH and 
PROMIS- UE were subsequently added. One clinic visit in 
addition to virtual follow- up was included and follow- up 
was adjusted to 3 and 6 months following patient discus-
sions. Feedback from patients who attended the work-
shop has informed all aspects of the research including 
research design, choice of outcome measures and length 
and location of follow- up.
The study protocol, participant information sheets 
and consent forms have been reviewed by PPI members, 
with feedback provided to optimise their utility. We 
have set up a Metacarpal Shaft Fracture Patient Advi-
sory Group to inform the design, delivery and output 
of the research. An electronic PPI platform has been 
created on the Centre for Evidence Based Hand 
Surgery (CEBHS) website to encourage regular input 
from patients/public.
Feedback from the Metacarpal Shaft Fracture Patient 
Advisory Group will guide distribution of findings to the 
public. This will include, but not be limited to, newslet-
ters, local media outlets, events and plain English summa-
ries of all published journal articles.
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Incorporating patient and public involvement in all 
aspects of the research pathway, from research design 
to co- development and review of all study documents, 
supports our commitment to ensuring sustained and 
meaningful PPI throughout the study.
Study management
The study is funded by a National Institute for Health 
Research Doctoral Fellowship awarded to Miss Rowa 
Taha (NIHR300197). It is sponsored by the University of 
Nottingham and will be managed and co- ordinated from 
the Centre for Evidence Based Hand Surgery (CEBHS), 
University of Nottingham.
ETHICS AND DISSEMINATION
Ethics committee and regulatory approvals
This study has received approval from the Research Ethics 
Committee (REC), the respective NHS Research & Devel-
opment (R&D) departments and the Health Research 
Authority (HRA) (REC reference 20/EE/0124). It will 
be conducted in accordance with the ethical principles 
that have their origin in the Declaration of Helsinki29; the 
principles of Good Clinical Practice30 and the UK Depart-
ment of Health Policy Framework for Health and Social 
Care, 2017.31
Informed consent
The process for obtaining participant informed consent 
will be in accordance with the REC guidance and Good 
Clinical Practice.30 The investigator or their nominee and 
the participant or other legally authorised representa-
tive shall both sign and date the informed consent form 
before the person can participate in the study. Written 
informed consent will be separately sought for taking part 
in the qualitative study.
Safety considerations and data protection
There are no significant safety issues with this study. The 
study is observational and does not interfere with the 
routine clinical care pathway. The treatments participants 
receive are widely available within the National Health 
Service and will not be altered by taking part in the 
study. The questionnaires, interviews and focus groups 
are neither burdensome nor contain sensitive questions 
and all reasonable expenses, such as travel and parking 
costs, associated with attending research visits will be fully 
reimbursed.
All study staff and investigators will endeavour to 
protect the rights of the study’s participants to privacy 
and informed consent and will adhere to the Data Protec-
tion Act, 2018.32 Case report forms will be held securely 
and access to the information will be limited to the study 
staff, investigators and relevant regulatory authorities. 
Computer held data including the study database will 
be held securely and password protected. All data will be 
stored on a secure dedicated web server. Access will be 
restricted by user identifiers and passwords (encrypted 
using a one- way encryption method).
Dissemination
Results of this study will be reported fully and made 
publicly available when the research has been completed. 
The outcomes of the study will be published in suit-
able peer- reviewed journals and will be reported locally, 
nationally and internationally in the form of presenta-
tions. Reporting will be in compliance with Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines.33 In order to fulfil reporting 
guidelines, a copy of the research paper will also be sent 
to the National Institute for Health Research (NIHR) 
programme issuing the funding contract.
The findings will be presented at national and interna-
tional meetings of relevant scientific societies. We will also 
publish key findings on the CEBHS website, and via the 
‘Hand Evidence Updates’, distributed by the CEBHS to 
over 800 national and international members.
Social media platforms will also be used to maximise 
dissemination of key findings as supported by evidence 
from the Nottingham Clinical Trials Unit.34 35
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